Abstract

Goal: Retinal prosthesis performance is limited by the variability of elicited phosphenes. The stimulating electrode's position with respect to retinal ganglion cells (RGCs) affects both perceptual threshold and phosphene shape. We created a modeling framework incorporating patient-specific anatomy and electrode location to investigate RGC activation and predict inter-electrode differences for one Argus II user. Methods: We used ocular imaging to build a three-dimensional finite element model characterizing retinal morphology and implant placement. To predict the neural response to stimulation, we coupled electric fields with multi-compartment cable models of RGCs. We evaluated our model predictions by comparing them to patient-reported perceptual threshold measurements. Results: Our model was validated by the ability to replicate clinical impedance and threshold values, along with known neurophysiological trends. Inter-electrode threshold differences in silico correlated with in vivo results. Conclusions: We developed a patient-specific retinal stimulation framework to quantitatively predict RGC activation and better explain phosphene variations.

Highlights

  • R ETINITIS pigmentosa (RP) is a progressive degenerative disease that causes severe blindness, affecting over a million people worldwide [1]

  • We created a patient-specific retinal stimulation model accounting for overall eye shape, electronics case (EOC) position, microelectrode array (MEA) placement, retinal morphology, and fibrotic tissue growth

  • retinal ganglion cells (RGCs) models had a simplified morphometry with a 90° bend, including a soma, axon hillock, sodium channel band (SOCB), narrow region, and distal axon. (Figure 5(c)) [27], [28]

Read more

Summary

Introduction

R ETINITIS pigmentosa (RP) is a progressive degenerative disease that causes severe blindness, affecting over a million people worldwide [1]. The disease results in photoreceptor death, preventing the transduction of light into neural. Manuscript received April 15, 2020; revised June 4, 2020; accepted June 7, 2020. Date of publication June 11, 2020; date of current version July 1, 2020. Weiland is with the Department of Biomedical Engineering and the Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, MI 48109 USA, and with the the Biointerfaces Institute, Ann Arbor MI 48105 USA (e-mail: weiland@ umich.edu)

Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call